Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Hyperpolarized 13C-Pyruvate Metabolic Magnetic Resonance Imaging for the Diagnosis and Risk-Stratification of Prostate Cancer

Trial Status: enrolling by invitation

This phase I trial tests the safety and effectiveness of an imaging scan called hyperpolarized 13C-pyruvate metabolic magnetic resonance imaging (MRI) in patients who are suspected or known to have prostate cancer. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. Metabolic MRI is a specialized type of MRI that uses a compound called hyperpolarized (HP)13 carbon (C)-pyruvate that when given by injection is taken up by tumor cells. In addition to imaging the prostate, as a standard MRI does, HP 13C MRI can also show areas of abnormal metabolism within the prostate. Prostate cancer cells have a metabolism that is different from normal cells and this agent can help to detect and visualize these tumor cells. Adding hyperpolarized 13C-pyruvate MRI may help researchers understand if metabolic MRI can improve the ability to diagnose and identify risk factors in prostate cancer.